Literature DB >> 15004773

CC chemokine receptor 5delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation.

Christian Moench1, Anja Uhrig, Ansgar W Lohse, Gerd Otto.   

Abstract

Ischemic-type biliary lesions are a major complication following orthotopic liver transplantation. They occur in up to 26% of liver transplant recipients. Among other factors, unknown immunologic factors have always been assumed to be partly responsible for these lesions. CC-chemokines and their receptors play a key role in postoperative immunomodulation after liver transplantation. The non-function CC-chemokine receptor 5delta32 polymorphism (CCR5delta32) has been shown to lead to a lower rate of acute rejection after kidney transplantation; in liver transplantation the role of CCR5delta32 is unclear. We investigated the influence of the CCR5delta32 after liver transplantation with special regard to ischemic-type biliary lesions. The CC-chemokine receptor-5 (CCR5) of 146 recipients was analyzed by polymerase chain reaction to detect CCR5delta32 in blood samples of patients after liver transplantation. One hundred twenty patients with wild-type CCR5 and 26 patients with CCR5delta32 (1 homozygote, 25 heterozygote) were identified. Ischemic-type biliary lesions occurred in 14 of 120 patients with wild-type CCR5 and in 8 of 26 patients with CCR5delta32 polymorphism (P = = 0.01). 5 year patient survival with CCR5delta32 and CCR5 was 70% and 85%, respectively (P =.0067). Our results show that the CCR5delta32 is a significant risk factor for the development of ischemic-type biliary lesions after liver transplantation and leads to a reduction in 5-year survival. In conclusion, the CCR5 status should be screened prospectively before liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004773     DOI: 10.1002/lt.20095

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  13 in total

1.  Management of Biliary Strictures After Liver Transplantation.

Authors:  Nicolas A Villa; M Edwyn Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-05

2.  Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease.

Authors:  Christian A Wysocki; Qi Jiang; Angela Panoskaltsis-Mortari; Patricia A Taylor; Karen P McKinnon; Lishan Su; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

3.  Biliary complications following orthotopic liver transplantation: a 10-year audit.

Authors:  Nalaka Gunawansa; John L McCall; Andrew Holden; Lindsay Plank; Stephen R Munn
Journal:  HPB (Oxford)       Date:  2011-06       Impact factor: 3.647

Review 4.  Avoiding pitfalls: what an endoscopist should know in liver transplantation--part II.

Authors:  Sharad Sharma; Ahmet Gurakar; Cemalettin Camci; Nicolas Jabbour
Journal:  Dig Dis Sci       Date:  2008-12-17       Impact factor: 3.199

5.  Establishment of an animal model of ischemic type intrahepatic biliary lesion in rabbits.

Authors:  Qin-Song Sheng; Da-Zhi Chen; Ren Lang; Qiang He; Yong-Jiu Yang; Zhao-Wei Qu; De-Fang Zhao; Xiao-Sheng Zhang
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

6.  CCR5 and CXCR3 are dispensable for liver infiltration, but CCR5 protects against virus-induced T-cell-mediated hepatic steatosis.

Authors:  P J Holst; C Orskov; K Qvortrup; J P Christensen; A R Thomsen
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

7.  Histological examination and evaluation of donor bile ducts received during orthotopic liver transplantation--a morphological clue to ischemic-type biliary lesion?

Authors:  Torsten Hansen; David Hollemann; Michael B Pitton; Michael Heise; Maria Hoppe-Lotichius; Marcus Schuchmann; C James Kirkpatrick; Gerd Otto
Journal:  Virchows Arch       Date:  2012-05-17       Impact factor: 4.064

8.  Ischemia-Reperfusion Injury and Ischemic-Type Biliary Lesions following Liver Transplantation.

Authors:  Raffaele Cursio; Jean Gugenheim
Journal:  J Transplant       Date:  2012-02-29

Review 9.  Chemokines in chronic liver allograft dysfunction pathogenesis and potential therapeutic targets.

Authors:  Bin Liu; Jing Li; Lu-Nan Yan
Journal:  Clin Dev Immunol       Date:  2013-12-08

10.  Chemokine Receptor-5Delta32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation.

Authors:  Christoph Heidenhain; Gero Puhl; Christian Moench; Anja Lautem; Peter Neuhaus
Journal:  J Transplant       Date:  2009-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.